SMis 10th Annual Advances & Progress in Drug Design (APDD 2011)
Venue: Copthorne Tara Hotel
|Event Date/Time: Feb 21, 2011||End Date/Time: Feb 22, 2011|
|Registration Date: Feb 22, 2011|
|Early Registration Date: Oct 29, 2010|
Drugs have traditionally been discovered by synthesising compounds in a time-consuming multi-step processes against a multitude of in vitro / in vivo biological screens and further investigating the promising candidates for their pharmacokinetic (PK) properties, metabolism and potential toxicity.
Such a development process has resulted in high attrition rates with failures attributed to poor PK, efficacy, toxicity, adverse effects and various other factors.
Drug discovery and design today has been revolutionised by an explosion of biophyiscal, genomic, proteomic, process, in silico tools, structural information and fragment-based methods which have aided the development of drugs against hundreds of new targets and provided countless opportunities for future drug lead discovery and development.
SMi's 10th annual conference on Advances & Progress in Drug Design will address the latest developments in this rapidly evolving field and look beyond to the next generation of tools, methods and technologies to aid rational drug design.
This conference will build upon a strong scientific reputation, featuring key leaders in the field of drug design delivering case study focused presentations with a practical theme enabling you to learn from the best.
The conference will address:
- Taking advantage of all the tools available to aid rational drug design - Identify the challenges, opportunities and learning from important lessons in the use of structure- and fragment- based drug design on various targets
- Lead generation perspectives and reducing compound attrition rates - Learn how pharma is using fragment-based methods and molecular drug design, and how you can shorten the time to a successful hit-to-lead campaign
- The role of waters in design - When to target water, novel in silico tools for predicting small molecule binding affinities and case studies addressing how best to utilise this information in design
- Fragment-based drug design - Does it deliver higher quality leads, identification and evaluation of the best performing fragment-specific docking and scoring protocols, progressing hits in the absence of crystal structures, and much more
- Looking towards the future - Novel methods to exploit available information, quantifying the role of computational chemistry expertise and how to effectively convey components of that expertise along with future technologies, and aromatic ring systems as drug components
- Networking - Share valuable experiences and network with key industry figures